Bmb-101
Lennox Gastaut Syndrome
Bright Minds Biosciences Pty LtdPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Lennox Gastaut Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
gwp42003-p Jazz Pharmaceuticals | Phase 4 | BBB |
Rufinamide Eisai Co., Ltd. | Phase 3 | BB |
Benzeneethanamine, N-ethyl-?-methyl-4-(trifluoromethyl)-, hydrochloride, (±)- University of Chicago | Phase 3 | BB |
zx008 Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | Phase 3 | BB |
Bexicaserin Longboard Pharmaceuticals | Phase 2 | BB |
View all 14 →
Same molecule, other indications
Bmb-101 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →